Promomed's revenue in Q1 2025 increased by 86% to ₽4,485 million. The revenue growth rate is more than five times higher than that of the pharmaceutical market, which grew by 16%. The share of revenue from sales of innovative products increased to 69% from 58% a year earlier. The share of Endocrinology and Cancer portfolios in revenue for the first quarter of 2025 was 65%, which is due to the faster growth rates of these segments, as well as the introduction of new drugs to the market.